ANGELA KOKINAKOS: Open Payments
NPI 1336786920 · EVERETT, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,910 in 63 payments from 12 companies in 2025. Trend: 2023 $1,556 · 2024 $2,828 · 2025 $3,910
Food & beverage: $3,910
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $767 |
| Axsome Therapeutics, Inc. | 10 | $712 |
| Neurocrine BioSciences, Inc. | 10 | $672 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $575 |
| E.R. Squibb & Sons, L.L.C. | 8 | $394 |
| Otsuka America Pharmaceutical, Inc. | 8 | $270 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $147 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Alkermes, Inc. | 1 | $114 |
| Teva Pharmaceuticals USA, Inc. | 1 | $89 |
Products named: VRAYLAR, Auvelity, INGREZZA, CAPLYTA, COBENFY, ABILIFY MAINTENA, REXULTI, FANAPT.
Industry payments across WA — which companies pay providers there.
